Mirum Pharmaceuticals (MIRM) Common Equity (2018 - 2026)

Mirum Pharmaceuticals' Common Equity history runs 9 years deep, the most recent figure standing at $242.5 million for Q1 2026.

• On a quarterly basis, Common Equity rose 3.96% year-over-year to $242.5 million in Q1 2026; TTM through Mar 2026 was $242.5 million, a 3.96% increase from a year earlier, with the FY2025 full-year figure at $314.7 million, up 39.47% from the prior year.
• Common Equity fell to $242.5 million in Q1 2026 per MIRM's latest filing, from $314.7 million in the prior quarter.
• Across five years, Common Equity topped out at $314.7 million in Q4 2025 and bottomed at $78.6 million in Q2 2023.
• The 5-year median for Common Equity is $232.0 million (2024), against an average of $207.5 million.
• Across the five-year window, Common Equity jumped 200.19% in 2022 and declined 28.98% in 2023, its largest moves.
• Year by year, Common Equity stood at $142.0 million in 2022, then jumped by 75.07% to $248.7 million in 2023, then fell by 9.26% to $225.6 million in 2024, then jumped by 39.47% to $314.7 million in 2025, then retreated by 22.94% to $242.5 million in 2026.
• Per Business Quant, the three latest MIRM Common Equity figures stand at $242.5 million (Q1 2026), $314.7 million (Q4 2025), and $292.0 million (Q3 2025).